A Study of Intensive-Dose Melphalan, Topotecan, and VP-16 Phosphate (MTV) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma

Trial Profile

A Study of Intensive-Dose Melphalan, Topotecan, and VP-16 Phosphate (MTV) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 May 2017

At a glance

  • Drugs Etoposide phosphate (Primary) ; Topotecan (Primary) ; Melphalan
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 17 May 2017 Planned End Date changed from 1 Nov 2017 to 28 Feb 2018.
    • 13 Dec 2016 Planned End Date changed from 1 Feb 2017 to 1 Nov 2017.
    • 05 Jul 2016 Planned End Date changed from 1 Dec 2016 to 1 Feb 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top